Alfonso Catalano

Summary

Country: Italy

Publications

  1. ncbi request reprint New aspects on the role of lipoxygenases in cancer progression
    A Catalano
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Via Ranieri, 60131 Ancona, Italy
    Histol Histopathol 20:969-75. 2005
  2. ncbi request reprint Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function
    Alfonso Catalano
    Dipartimento di Patologia Molecolare, Politecnica delle Marche, Via Ranieri, 60131, Ancona, Italy
    Blood 107:3321-9. 2006
  3. pmc 5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona, Italy
    EMBO J 24:170-9. 2005
  4. ncbi request reprint 5-lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona, Italy
    FASEB J 18:1740-2. 2004
  5. ncbi request reprint Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona 60131, Italy
    J Biol Chem 279:46706-14. 2004
  6. ncbi request reprint Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona, Italy
    Int J Cancer 109:322-8. 2004
  7. ncbi request reprint Cross-talk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Laboratory of Experimental Pathology, Polytechnic University of Marche, Ancona, Italy
    FASEB J 18:358-60. 2004
  8. pmc Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis
    Daniele Martarelli
    Department of Experimental Medicine and Public Health, University of Camerino, 62032 Camerino, Italy
    BMC Cancer 6:130. 2006
  9. doi request reprint Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma
    Raffaella Lazzarini
    Department of Molecular Pathology and Innovative Therapies, Marche University, Ancona, Italy
    Clin Cancer Res 14:5099-107. 2008
  10. ncbi request reprint FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells
    Maria Rita Rippo
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, 60100 Ancona, Italy
    Oncogene 23:7753-60. 2004

Collaborators

Detail Information

Publications16

  1. ncbi request reprint New aspects on the role of lipoxygenases in cancer progression
    A Catalano
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Via Ranieri, 60131 Ancona, Italy
    Histol Histopathol 20:969-75. 2005
    ..Moreover, we discuss how this new perspective on the roles of LOXs and their metabolites can have important implications to cancer therapy...
  2. ncbi request reprint Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function
    Alfonso Catalano
    Dipartimento di Patologia Molecolare, Politecnica delle Marche, Via Ranieri, 60131, Ancona, Italy
    Blood 107:3321-9. 2006
    ..These results suggest that Sema-3A inhibits primary T-cell activation and imply that it can contribute to the T-cell dysfunction in the tumor microenvironment...
  3. pmc 5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona, Italy
    EMBO J 24:170-9. 2005
    ..These data link the 5LO pathway to oxidative crises of primary fibroblast and suggest that the ability of 5LO to induce senescence-like growth arrest may be important in the pathogenesis of 5LO-associated disorders...
  4. ncbi request reprint 5-lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona, Italy
    FASEB J 18:1740-2. 2004
    ..Moreover, they provide a rationale to the therapeutic use of 5-LO inhibitors to enhance cancer chemosensitivity in selected tumors...
  5. ncbi request reprint Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona 60131, Italy
    J Biol Chem 279:46706-14. 2004
    ....
  6. ncbi request reprint Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona, Italy
    Int J Cancer 109:322-8. 2004
    ..These data demonstrate that celecoxib may have antitumor properties in MM and provide a rationale for the therapeutic use of celecoxib in combination with a selective VEGF inhibitor...
  7. ncbi request reprint Cross-talk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Laboratory of Experimental Pathology, Polytechnic University of Marche, Ancona, Italy
    FASEB J 18:358-60. 2004
    ..Therefore, these results delineate a new role of Sema-3A in VEGF function mediated by p38 MAPK and suggest that the abrogation of regulated Sema-3A expression is responsible for VEGF-driven growth of tumor cells...
  8. pmc Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis
    Daniele Martarelli
    Department of Experimental Medicine and Public Health, University of Camerino, 62032 Camerino, Italy
    BMC Cancer 6:130. 2006
    ..Our work aimed at establishing a nude mouse model xenotransplanted with human MPM cell lines in which tumor progression exhibits some features of the human disease...
  9. doi request reprint Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma
    Raffaella Lazzarini
    Department of Molecular Pathology and Innovative Therapies, Marche University, Ancona, Italy
    Clin Cancer Res 14:5099-107. 2008
    ..Recent data indicate that p21 keeps tumor cells alive after DNA damage, favoring a survival advantage. In this study, we assessed the possibility of p21 suppression as a therapeutic target for MPM...
  10. ncbi request reprint FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells
    Maria Rita Rippo
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, 60100 Ancona, Italy
    Oncogene 23:7753-60. 2004
    ..These results indicate that MM cells develop an intrinsic resistance to apoptosis induced by death receptors upregulating the expression of the antiapoptotic protein c-FLIP...
  11. doi request reprint The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Marche University, Ancona, Italy
    Cancer Res 69:1485-93. 2009
    ..This work identifies a new biological function of semaphorins in cancer cells and suggests the involvement of an undescribed survival pathway during MPM tumorigenesis...
  12. ncbi request reprint Semaphorin3A signaling controls Fas (CD95)-mediated apoptosis by promoting Fas translocation into lipid rafts
    Simona Moretti
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona, Italy
    Blood 111:2290-9. 2008
    ..This work identifies a novel biologic function of semaphorins and presents an unexpected signaling mechanism linking semaphorin to the tumor necrosis factor family receptors...
  13. ncbi request reprint Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen
    Alfonso Catalano
    Institute of Experimental Pathology, University of Ancona, Faculty of Medicine, Via Ranieri, 60131 Ancona, Italy
    Oncogene 21:2896-900. 2002
    ..These data indicate that VEGF regulation by SV40 transforming proteins can represent a key event in SV40 signaling relevant for tumor progression...
  14. doi request reprint The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona, Italy
    J Immunol 185:6373-83. 2010
    ....
  15. ncbi request reprint Neuronal semaphorins regulate a primary immune response
    Simona Moretti
    Department of Molecular Pathology and Innovative Therapies, Marche Polytechnic University, Ancona, Italy
    Curr Neurovasc Res 3:295-305. 2006
    ..This paper discusses the functions of these semaphorins in the immune system, focusing on their roles in T cell-APC interactions...
  16. ncbi request reprint Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments
    Alfonso Catalano
    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Via Ranieri 6, Ancona 60131, Italy
    Crit Rev Oncol Hematol 50:101-9. 2004
    ..It seems likely that no single treatment modality will be effective by itself. Studies that use combinations of the newer agents, including angiostatic drugs, with chemotherapy, should be conducted...